Your browser doesn't support javascript.
COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control.
Buchy, Philippe; Buisson, Yves; Cintra, Otavio; Dwyer, Dominic E; Nissen, Michael; Ortiz de Lejarazu, Raul; Petersen, Eskild.
  • Buchy P; GSK, Singapore, Singapore. Electronic address: philippe.x.buchy@gsk.com.
  • Buisson Y; Académie nationale de médecine, Paris, France. Electronic address: yvesbuisson@hotmail.com.
  • Cintra O; GSK, Rio de Janeiro, Brazil. Electronic address: otavio.a.cintra@gsk.com.
  • Dwyer DE; New South Wales Health Pathology - Institute of Clinical Pathology and Medical Research, Westmead Hospital, New South Wales, Australia. Electronic address: dominic.dwyer@sydney.edu.au.
  • Nissen M; Consultant in Infectious Diseases, University of Queensland, Brisbane, Australia. Electronic address: theniss@uq.edu.au.
  • Ortiz de Lejarazu R; Scientific Advisor & Emeritus director at Valladolid NIC (National Influenza Centre) Spain, School of Medicine, Avd Ramón y Cajal s/n 47005 Valladolid, Spain. Electronic address: lejarazu@gmail.com.
  • Petersen E; European Society for Clinical Microbiology and Infectious Diseases, Basel, Switzerland; Department of Molecular Medicine, The University of Pavia, Pavia, Italy; Department of Clinical, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electronic address: eskild.petersen@gmail.com.
Int J Infect Dis ; 112: 300-317, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1654547
ABSTRACT
Pandemic dynamics and health care responses are markedly different during the COVID-19 pandemic than in earlier outbreaks. Compared with established infectious disease such as influenza, we currently know relatively little about the origin, reservoir, cross-species transmission and evolution of SARS-CoV-2. Health care services, drug availability, laboratory testing, research capacity and global governance are more advanced than during 20th century pandemics, although COVID-19 has highlighted significant gaps. The risk of zoonotic transmission and an associated new pandemic is rising substantially. COVID-19 vaccine development has been done at unprecedented speed, with the usual sequential steps done in parallel. The pandemic has illustrated the feasibility of this approach and the benefits of a globally coordinated response and infrastructure. Some of the COVID-19 vaccines recently developed or currently in development might offer flexibility or sufficiently broad protection to swiftly respond to antigenic drift or emergence of new coronaviruses. Yet many challenges remain, including the large-scale production of sufficient quantity of vaccines, delivery of vaccines to all countries and ensuring vaccination of relevant age groups. This wide vaccine technology approach will be best employed in tandem with active surveillance for emerging variants or new pathogens using antigen mapping, metagenomics and next generation sequencing.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article